医学
前瞻性队列研究
不利影响
磁共振成像
癫痫
放射科
核医学
相关性
中枢神经系统疾病
内科学
外科
化疗
动态增强MRI
脑电图
临床试验
文本挖掘
中止
星形细胞瘤
混淆
还原(数学)
作者
Roberta Rudà,Francesco Bruno,Edoardo Pronello,Alessia Pellerino,Francesca Scalvini,Marco Conti Nibali,Marco Rossi,Tommaso Sciortino,Lorenzo Gabriel Gay,Alberto Luigi Gallotti,Fabio Cofano,Giovanni Morana,Gianluca Nocera,Antonella Castellano,Andrea Falini,Federico Ponzetto,Laura Leoni,Alessia Melis,Giulio Mengozzi,Alessia Andrea Ricci
标识
DOI:10.1093/neuonc/noag282
摘要
BACKGROUND: The IDH1/2 inhibitor vorasidenib demonstrated efficacy in residual or recurrent grade 2 IDH1/2-mutant gliomas after surgery. However, there is lack of knowledge regarding factors predicting the probability of response. PATIENTS AND METHODS: We conducted a prospective single-centre study on 54 grade 2 IDH1/2-mutant astrocytomas and IDH1/2-mutant 1p/19q-codeleted oligodendrogliomas treated with vorasidenib. MRI response (2D and 3D) and seizure outcome were longitudinally assessed. Factors associated with response were explored using regression models. RESULTS: With a median follow-up of 17.5 months, vorasidenib induced progressive tumour shrinkage on MRI, with median volume reductions of - 12.2% at cycle 6, -27.8% at cycle 12, and -55.5% at cycle 18. Best volumetric response was CR in 1 patient, PR in 5, MR in 9, SD in 31 and PD in 7. The ORR (CR + PR + MR) was 28%. Eighteen patients who had focal grade 3 areas showed similar volumetric response and ORR. 9/12 (75%) patients with baseline seizures achieved ≥50% reduction or seizure freedom. MRI response correlated with early treatment initiation and early seizure reduction. Vorasidenib was generally well tolerated, with liver enzyme elevation being the main adverse event. CONCLUSIONS: Vorasidenib induced sustained tumour shrinkage and seizure control. Early treatment initiation and early seizure reduction were associated with MRI response.
科研通智能强力驱动
Strongly Powered by AbleSci AI